Robert W. Baird Lowers IQVIA (NYSE:IQV) Price Target to $223.00

IQVIA (NYSE:IQV) had its price target lowered by investment analysts at Robert W. Baird from $256.00 to $223.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s target price would indicate a potential upside of 8.35% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. UBS Group raised their target price on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. decreased their price target on IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Truist Financial cut their price objective on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Finally, Barclays decreased their target price on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $265.07.

IQVIA Stock Performance

Shares of IQV stock opened at $205.82 on Friday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The business has a 50 day moving average of $235.10 and a two-hundred day moving average of $229.89. The company has a market cap of $37.52 billion, a P/E ratio of 26.73, a PEG ratio of 2.11 and a beta of 1.49. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Park Place Capital Corp purchased a new position in shares of IQVIA during the third quarter valued at $28,000. Versant Capital Management Inc boosted its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in IQVIA during the 2nd quarter valued at about $27,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the 2nd quarter valued at about $29,000. Finally, International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the second quarter worth approximately $32,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.